Tags

Type your tag names separated by a space and hit enter

Adjuvant endocrine therapy in postmenopausal breast cancer.
Clin Cancer Res. 2003 Jan; 9(1 Pt 2):480S-5S.CC

Abstract

Adjuvant endocrine therapy with tamoxifen has a clearly established benefit in postmenopausal women with resected early breast cancer that expresses the estrogen receptor and/or progesterone receptor. Whereas there is a vast and long experience with tamoxifen, the major focus of clinical trials over the past 6 years has involved the study of the third-generation aromatase inhibitors. Recently published data from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial, which involved only postmenopausal women and is the largest adjuvant trial ever conducted, has demonstrated superior efficacy for anastrozole over tamoxifen alone or in combination with anastrozole. These data have engendered a great deal of discussion as to whether they provide a sufficient basis for changing the standard of practice in terms of choice of agent. Currently, a case can be made that further maturation of the ATAC trial is necessary and that tamoxifen should remain the standard of endocrine adjuvant therapy for most women, with anastrozole being used in those with a contraindication or intolerance to tamoxifen. However, close attention must be paid to new information as it develops not only related to efficacy but also to other end organ effects.

Authors+Show Affiliations

Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA. ingle.james@mayo.edu

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

12538504

Citation

Ingle, James N.. "Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, vol. 9, no. 1 Pt 2, 2003, 480S-5S.
Ingle JN. Adjuvant endocrine therapy in postmenopausal breast cancer. Clin Cancer Res. 2003;9(1 Pt 2):480S-5S.
Ingle, J. N. (2003). Adjuvant endocrine therapy in postmenopausal breast cancer. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 9(1 Pt 2), 480S-5S.
Ingle JN. Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer. Clin Cancer Res. 2003;9(1 Pt 2):480S-5S. PubMed PMID: 12538504.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Adjuvant endocrine therapy in postmenopausal breast cancer. A1 - Ingle,James N, PY - 2003/1/23/pubmed PY - 2003/7/4/medline PY - 2003/1/23/entrez SP - 480S EP - 5S JF - Clinical cancer research : an official journal of the American Association for Cancer Research JO - Clin Cancer Res VL - 9 IS - 1 Pt 2 N2 - Adjuvant endocrine therapy with tamoxifen has a clearly established benefit in postmenopausal women with resected early breast cancer that expresses the estrogen receptor and/or progesterone receptor. Whereas there is a vast and long experience with tamoxifen, the major focus of clinical trials over the past 6 years has involved the study of the third-generation aromatase inhibitors. Recently published data from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial, which involved only postmenopausal women and is the largest adjuvant trial ever conducted, has demonstrated superior efficacy for anastrozole over tamoxifen alone or in combination with anastrozole. These data have engendered a great deal of discussion as to whether they provide a sufficient basis for changing the standard of practice in terms of choice of agent. Currently, a case can be made that further maturation of the ATAC trial is necessary and that tamoxifen should remain the standard of endocrine adjuvant therapy for most women, with anastrozole being used in those with a contraindication or intolerance to tamoxifen. However, close attention must be paid to new information as it develops not only related to efficacy but also to other end organ effects. SN - 1078-0432 UR - https://www.unboundmedicine.com/medline/citation/12538504/Adjuvant_endocrine_therapy_in_postmenopausal_breast_cancer_ DB - PRIME DP - Unbound Medicine ER -